BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.